Novo Nordisk is a Danish multinational pharmaceutical company that develops and markets medicines, with a major focus on diabetes and obesity treatment.
No entity score yet. This entity needs at least one linked article with an entity impact vote and focus support.
Showing 1-2 of 2 linked articles
Page 1 of 1
The FDA warned Novo Nordisk that it failed to report possible serious side effects from its GLP-1 drugs, including Ozempic and Wegovy, on time.
Per-entity impact from this article: None
Novo Nordisk has launched a weight-loss pill version of Wegovy in the U.S., giving patients a new oral option for obesity treatment.
Per-entity impact from this article: None